인도의 혈당 측정기 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the India blood glucose monitoring devices market size was valued at USD 406.92 million in 2025 and estimated to grow from USD 440.09 million in 2026 to reach USD 651.12 million by 2031, at a CAGR of 8.15% during the forecast period (2026-2031).

This report is Segmented by Product Type (Self-Monitoring Blood Glucose Devices [Glucometer Devices, and More], Continuous Glucose Monitoring Systems [Sensors and Durables]), End User (Hospitals & Clinics, Home-Care Settings, Diagnostic Centers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

India Blood Glucose Monitoring Devices Market Trends and Insights

Growing Diabetes Prevalence & Earlier Screening

National screening drives have identified an addressable base of more than 100 million people, including 25-30 million undiagnosed cases, lifting demand across all categories in the India blood glucose monitoring devices market. Screening at primary-care facilities now detects disease five to seven years earlier than a decade ago, stretching each patient's lifetime need for monitoring devices to as long as three decades. Intensive screening in semi-urban belts is accelerating device uptake among younger cohorts that show higher comfort with connected solutions. This shift is also guiding policymakers to support reimbursement for continuous monitoring because early adopters achieve superior glycemic control, lowering long-run complication costs. Collectively, these factors add more than +2.0 percentage points to the forecast CAGR of the India blood glucose monitoring devices market.

Rapid Penetration of Affordable SMBG Strips via Jan Aushadhi Stores

The Jan Aushadhi network supplies strips at half to one-tenth the branded price, cutting monthly monitoring outlay to INR 300-500 and doubling average weekly testing frequency. Affordable consumables are unlocking latent demand in Tier 2/3 cities where branded glucometer ownership languished below 15% as recently as 2022. Higher test-strip throughput improves glycemic control, reinforcing device stickiness and encouraging private manufacturers to introduce value-engineered meters tailored for these price-sensitive markets. The surge in strip volumes exerts significant positive pressure on the India blood glucose monitoring devices market, reflected in a +1.8% uplift to CAGR forecasts.

Fragmented Physician Rx Habits Favoring Legacy Glucometers

General practitioners deliver 70% of diabetes care but allocate only three to five minutes per visit, limiting discussion of advanced monitoring tools. As a result, many continue prescribing older glucometers they first encountered in medical school. Rural clinicians, serving two-thirds of the population, rarely receive manufacturer training on continuous systems, perpetuating brand inertia that slows CGM diffusion. Inconsistent guidance across multiple providers confuses patients and depresses adherence to optimal testing regimes. This entrenched conservatism removes roughly 1.4 percentage points from projected CAGR for the India blood glucose monitoring devices market.

Other drivers and restraints analyzed in the detailed report include:

1. Widespread Adoption of Tele-diabetes Platforms Post-COVID-19
2. GST Reductions on Essential Diabetes Devices
3. Grey-Market Import of Low-Quality Strips Diluting Brand Trust

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Self-monitoring blood glucose devices generated 83.70% of 2025 revenue, primarily via meter-strip bundles sold at INR 800-1,500 and replenished with low-cost consumables distributed through Jan Aushadhi outlets. Test strips remain the largest contributor because each new reader drives recurring consumable demand. However, continuous glucose monitoring sensors outpace overall market growth at an 8.78% CAGR as price points fall and clinical outcome data becomes mainstream. The potential launch of a domestic INR 1,000/month CGM solution by FY26 could reset affordability and spur mass adoption.

The SMBG base maintains steady expansion because first-time buyers in Tier 2/3 cities continue to prefer upfront affordability and simple operation. Yet endocrinologists in metros are shifting high-risk patients to continuous sensors that capture glycemic variability and minimize nocturnal hypoglycemia. If domestic price compression materializes, the India blood glucose monitoring devices market size for CGM could triple its 2024 base by 2030, progressively eroding SMBG share. Leading brands now bundle cloud dashboards with traditional meters to defend position, reflecting the converging feature set between the two categories.

Complete Report Scope:

• By Product Type
  • Self-Monitoring Blood Glucose (SMBG) Devices
    • Glucometer Devices
    • Test Strips
    • Lancets
  • Continuous Glucose Monitoring (CGM) Systems
    • Sensors
    • Durables (Receivers and Transmitters)
• By End User
  • Hospitals & Clinics
  • Home-Care Settings
  • Diagnostic Centers
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Roche Diabetes Care AG
3. Medtronic
4. Dexcom
5. Ascensia Diabetes Care Holdings AG
6. Lifescan
7. Arkray
8. i-SENS Inc.
9. Terumo
10. Ypsomed
11. SD Biosensor Inc.
12. Nova Biomedical
13. B. Braun
14. Morepen Laboratories Ltd.
15. Acon Laboratories
16. Sinocare
17. Mankind Pharma Ltd.
18. Truworth Health Tech Pvt Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing diabetes prevalence & earlier screening
  • 4.2.2 Rapid penetration of affordable SMBG strips via Jan Aushadhi stores
  • 4.2.3 Widespread adoption of tele-diabetes platforms post-COVID-19
  • 4.2.4 GST reductions on essential diabetes devices
  • 4.2.5 Insurance regulator mandating CGM reimbursement
  • 4.2.6 App-linked loyalty programs boosting test-strip adherence
• 4.3 Market Restraints
  • 4.3.1 Fragmented physician Rx habits favouring legacy glucometers
  • 4.3.2 Grey-market import of low-quality strips diluting brand trust
  • 4.3.3 Low public-hospital budget for CGM procurement
  • 4.3.4 Data-privacy concerns over cloud-linked monitoring apps
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD Million)

• 5.1 By Product Type
  • 5.1.1 Self-Monitoring Blood Glucose (SMBG) Devices
    • 5.1.1.1 Glucometer Devices
    • 5.1.1.2 Test Strips
    • 5.1.1.3 Lancets
  • 5.1.2 Continuous Glucose Monitoring (CGM) Systems
    • 5.1.2.1 Sensors
    • 5.1.2.2 Durables (Receivers and Transmitters)
• 5.2 By End User
  • 5.2.1 Hospitals & Clinics
  • 5.2.2 Home-Care Settings
  • 5.2.3 Diagnostic Centers
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Roche Diabetes Care AG
  • 6.3.3 Medtronic plc
  • 6.3.4 Dexcom Inc.
  • 6.3.5 Ascensia Diabetes Care Holdings AG
  • 6.3.6 LifeScan Inc.
  • 6.3.7 Arkray Inc.
  • 6.3.8 i-SENS Inc.
  • 6.3.9 Terumo Corporation
  • 6.3.10 Ypsomed Holding AG
  • 6.3.11 SD Biosensor Inc.
  • 6.3.12 Nova Biomedical
  • 6.3.13 B. Braun Melsungen AG
  • 6.3.14 Morepen Laboratories Ltd.
  • 6.3.15 ACON Laboratories Inc.
  • 6.3.16 Sinocare Inc.
  • 6.3.17 Mankind Pharma Ltd.
  • 6.3.18 Truworth Health Tech Pvt Ltd

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment